New cancer pill targets genetic weakness in advanced tumors
NCT ID NCT05838768
Summary
This early-stage trial is testing a new oral drug called HRO761, both alone and combined with other cancer therapies, for people with advanced solid tumors that have specific genetic changes (MSI-High or dMMR). The main goals are to find safe and effective dose levels and to see how well the body handles the drug. The study includes 327 participants whose cancer has progressed after standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSIHI OR DMMR ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS, INCLUDING COLORECTAL CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Medical Ctr
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering
New York, New York, 10017, United States
-
Novartis Investigative Site
Brussels, 1200, Belgium
-
Novartis Investigative Site
Beijing, 100036, China
-
Novartis Investigative Site
Guangzhou, 510655, China
-
Novartis Investigative Site
Bordeaux, 33076, France
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
Jena, Thuringia, 07740, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Kashiwa, Chiba, 2778577, Japan
-
Novartis Investigative Site
Oslo, 0310, Norway
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Seoul, 03722, South Korea
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28040, Spain
-
Novartis Investigative Site
Valencia, 46010, Spain
-
Novartis Investigative Site
Stockholm, 17176, Sweden
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Novartis Investigative Site
London, SW3 6JJ, United Kingdom
-
Novartis Investigative Site
Oxford, OX3 7LE, United Kingdom
-
UCSF
San Francisco, California, 94115, United States
-
Univ of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
University of California LA
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.